Zealand Pharma teams with Generate Biomedicines on AI-based obesity treatments

Bloomberg reports that Zealand Pharma and Generate Biomedicines are teaming up to develop obesity treatments using AI. The agreement initially covers two experimental drug programs, with an option for a third. Zealand will pay Generate $30 million upfront and $35 million for early milestones; total payments could reach nearly $1.2 billion through research, development, regulatory and commercial milestones, according to a document Bloomberg reviewed.